fbpx
Menu

Aduro Biotech Presents Preliminary Results from Ongoing Phase 1 Trials of STING agonist ADU-S100 (MIW815) in Patients with Advanced Solid Tumors or Lymphomas well-tolerated with no dose-limiting toxicities reported

Share

Single agent data supports further evaluation of ADU-S100 in combination with checkpoint inhibitor therapies

BERKELEY, Calif., November 9, 2018 Aduro Biotech, Inc. (NASDAQ: ADRO) today announced presentation of preliminary data from its ongoing Phase 1 dose-finding study of ADU-S100 (MIW815), a novel STING (stimulator of interferon genes) pathway activator, at SITC 2018 in Washington, D.C. Aduro and collaborator Novartis embarked on this first-in-human trial (see www.clinicaltrials.gov, identifier NCT02675439) as an important first step in characterizing the safety profile and mechanism of ADU-S100 and its ability to activate the STING pathway. …

[Read on via official release]

Source: US SEC
View full document:
EX-991_of_8-K_for_ADURO_BIOTECH_INC__8-K-11-09-2018